Foord S M, Peters J R, Dieguez C, Scanlon M F, Hall R
Endocrinology. 1983 May;112(5):1567-77. doi: 10.1210/endo-112-5-1567.
Dopamine (DA) and the dopaminergic agonists bromocriptine and apomorphine inhibit the secretion of TSH as well as that of PRL by rat anterior pituitary (AP) cells in monolayer culture. The order of potency of the drugs is the same for the inhibition of both hormones: bromocriptine ED50 = 0.006 nM against PRL and 0.017 nM against TSH; apomorphine ED50 = 2.9 and 4.8 nM, respectively, and DA, ED50 = 30 and 370 nM, respectively. The dopaminergic antagonists domperidone (DOM) and metoclopramide prevent the inhibition of TSH and PRL by 10(-6) M DA (IC50 = 0.012 and 0.32 nM for metoclopramide against PRL and TSH, respectively; similarly, IC50 = 0.01 and 0.61 nM for DOM). The action of butaclamol is shown to be stereospecific, in that the (+) isomer is 1000-fold more potent in reversing the inhibition of both TSH and PRL by 10(-6) M DA than the (-) isomer [IC50 = 1.1 and 7200 nM for the (+) and (-) isomers against PRL; similarly, 6.3 and 2600 nM against TSH]. The use of radioligand-binding techniques with tritiated DOM ([3H]DOM) and dihydroergocriptine ([3H]DHE) has demonstrated a high affinity dopaminergic binding site upon rat AP cells under the same conditions as the cell cultures used in the hormone secretion studies. Both ligands have been shown to label a site with high affinity (Kd = 1-2 nM) and low capacity (2-3 fmol/10(5) cells). At this site, dopaminergic agonists and antagonists compete with both radioligands and display a rank order of potency which is the same as that shown against TSH and PRL secretion and which is typically dopaminergic. For [3H]DHE: bromocriptine Ki (0.04 nM) greater than metoclopramide = DOM (0.07 nM) greater than (+)butaclamol (0.7 nM) greater than apomorphine (20 nM) greater than DA (700 nM) greater than (-)butaclamol (2000 nM). Similar data were derived using [3H]DOM. The high affinity site is saturable, has rapid association and dissociation rates, as determined for both radioligands used, and is temperature dependent. In contrast, both radioligands bind to a second binding site on the cells that is of lower affinity (Kd = 244 nM for [3H]DOM and 678 nM for [3H]DHE) and larger capacity (100 fmol/10(5) cells for both ligands). This second site is neither stereospecific nor, using the methodology presented here, does it discriminate between other dopaminergic compounds. It is thus not considered to represent specific DA receptor binding. It is concluded that the dopaminergic stimulus causing the inhibition of TSH and PRL secretion from rat AP cells in culture is mediated via a high affinity DA receptor present upon lactotrophs and thyrotrophs and that this receptor has similar characteristics on the two cell types.
多巴胺(DA)以及多巴胺能激动剂溴隐亭和阿扑吗啡可抑制单层培养的大鼠垂体前叶(AP)细胞分泌促甲状腺激素(TSH)和催乳素(PRL)。这两种药物抑制这两种激素分泌的效力顺序相同:溴隐亭对PRL的半数有效浓度(ED50)=0.006 nM,对TSH的ED50 = 0.017 nM;阿扑吗啡对PRL和TSH的ED50分别为2.9和4.8 nM,而DA对PRL和TSH的ED50分别为30和370 nM。多巴胺能拮抗剂多潘立酮(DOM)和甲氧氯普胺可阻止10^(-6) M DA对TSH和PRL的抑制作用(甲氧氯普胺对PRL和TSH的半数抑制浓度(IC50)分别为0.012和0.32 nM;类似地,DOM对PRL和TSH的IC50分别为0.01和0.61 nM)。已证明布他拉莫的作用具有立体特异性,即(+)异构体在逆转10^(-6) M DA对TSH和PRL的抑制作用方面比(-)异构体强1000倍[(+)和(-)异构体对PRL的IC50分别为1.1和7200 nM;类似地,对TSH的IC50分别为6.3和2600 nM]。使用氚标记的DOM([3H]DOM)和二氢麦角隐亭([3H]DHE)的放射性配体结合技术已证明,在与激素分泌研究中使用的细胞培养相同的条件下,大鼠AP细胞上存在高亲和力的多巴胺能结合位点。两种配体均已显示标记一个具有高亲和力(解离常数(Kd)=1 - 2 nM)和低容量(2 - 3 fmol/10^5个细胞)的位点。在这个位点,多巴胺能激动剂和拮抗剂与两种放射性配体竞争,并显示出与对TSH和PRL分泌的抑制作用相同的效力顺序,这是典型的多巴胺能作用顺序。对于[3H]DHE:溴隐亭的抑制常数(Ki)(0.04 nM)大于甲氧氯普胺 = DOM(0.07 nM)大于(+)布他拉莫(0.7 nM)大于阿扑吗啡(20 nM)大于DA(700 nM)大于(-)布他拉莫(2000 nM)。使用[3H]DOM也得到了类似的数据。高亲和力位点是可饱和的,具有快速的结合和解离速率,这是针对所使用的两种放射性配体测定的,并且与温度有关。相比之下,两种放射性配体都与细胞上的第二个结合位点结合,该位点亲和力较低([3H]DOM的Kd = 244 nM,[3H]DHE的Kd = 678 nM)且容量较大(两种配体均为100 fmol/10^5个细胞)。这个第二个位点既没有立体特异性,使用本文介绍的方法也不能区分其他多巴胺能化合物。因此,它不被认为代表特异性的DA受体结合。结论是,在培养中导致大鼠AP细胞分泌TSH和PRL受到抑制的多巴胺能刺激是通过存在于催乳素细胞和促甲状腺激素细胞上的高亲和力DA受体介导的,并且该受体在两种细胞类型上具有相似的特征。